<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05044403</url>
  </required_header>
  <id_info>
    <org_study_id>MUL-HEMO</org_study_id>
    <nct_id>NCT05044403</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Extracorporeal Support With Hemoperfusion in Critical Patients With Multiorgan Dysfunction Syndrome by Septic Origin</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of Extracorporeal Support With Hemoperfusion in Critical Patients With Multiorgan Dysfunction Syndrome by Septic Origin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low-level interventional clinical trial to evaluate the effectiveness and safety of&#xD;
      extracorporeal support with hemoperfusion in critical patients with multiorgan dysfunction&#xD;
      syndrome by septic origin.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vasopressors dose</measure>
    <time_frame>During hemoperfusion</time_frame>
    <description>Analyze the patient's vasopressor dose during the hemoperfusion process</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vasopressors dose - Intensive Care Unit discharge</measure>
    <time_frame>Prior Intensive Care Unit discharge</time_frame>
    <description>Analyze the patient's vasopressor dose prior Intensive Care Unit discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vasopressors dose - Hospital discharge</measure>
    <time_frame>Prior Hospital discharge</time_frame>
    <description>Analyze the patient's vasopressor dose prior Hospital discharge</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vasopressors dose - 90 days post-Intensive Care Unit discharge</measure>
    <time_frame>90 days post-Intensive Care Unit discharge</time_frame>
    <description>Analyze the patient's vasopressor dose 90 days post-Intensive Care Unit discharge</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hemoperfusion</condition>
  <condition>Multiorgan Failure</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Conventional treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receiving conventional treatment for multiorganic dysfunction syndrome from septic origin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Extracorporeal support with haemoperfusion treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving extracorporeal support with haemoperfusion for multiorganic dysfunction syndrome from septic origin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Extracorporeal support with haemoperfusion</intervention_name>
    <description>Use of extracorporeal support with haemoperfusion</description>
    <arm_group_label>Extracorporeal support with haemoperfusion treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional treatment</intervention_name>
    <description>Conventional treatment</description>
    <arm_group_label>Conventional treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a sepsis diagnosis, according to the diagnostic criteria of the&#xD;
             International Sepsis-3 Consensus Conference, and without response to the treatment of&#xD;
             septic shock who meet the following conditions:&#xD;
&#xD;
          -  Sepsis of abdominal origin with controlled infectious focus.&#xD;
&#xD;
          -  Noradrenaline dose&gt; 0.5 µg / kg / min to maintain adequate organ perfusion after&#xD;
             optimization of fluid therapy.&#xD;
&#xD;
          -  Dysfunction of two or more organs with SOFA ≥ 9 (5).&#xD;
&#xD;
          -  Blood lactate ≥ 2 mmol / L.&#xD;
&#xD;
          -  Procalcitonin (PCT)&gt; 10 ng / mL.&#xD;
&#xD;
          -  CRP&gt; 100 mg / L.&#xD;
&#xD;
          -  IL-6&gt; 2000 pg / ml.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age under 18 years or over 80 years.&#xD;
&#xD;
          -  Pregnancy or breastfeeding.&#xD;
&#xD;
          -  Terminally ill patients or with a life expectancy of less than 48 hours.&#xD;
&#xD;
          -  Thrombocytopenia &lt;60,000 / mm3.&#xD;
&#xD;
          -  Pancytopenia.&#xD;
&#xD;
          -  Severe coagulopathy with high risk of bleeding.&#xD;
&#xD;
          -  Inclusion in another research protocol.&#xD;
&#xD;
          -  In case of re-entry during the study period, only the first admission will be&#xD;
             included.&#xD;
&#xD;
          -  Use of another haemoperfusion device.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fernando Sánchez Morán</last_name>
    <phone>964399914</phone>
    <email>fsanchez201x@cv.gva.es</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 3, 2021</study_first_submitted>
  <study_first_submitted_qc>September 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

